
Valérie Devauchelle-Pensec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10666628/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Joint involvement in Noonan syndrome. A retrospective paediatric descriptive study. Joint Bone Spine, 2022, 89, 105270.	0.8	2
2	Primary Sjögren's syndrome: new beginning for evidence-based trials. Lancet, The, 2022, 399, 121-122.	6.3	5
3	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	0.9	12
4	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.5	27
5	Aortic involvement in giant cell arteritis. Joint Bone Spine, 2021, 88, 105045.	0.8	6
6	Tocilizumab controls bone turnover in early polymyalgia rheumatica. Joint Bone Spine, 2021, 88, 105117.	0.8	5
7	Salivary Glands and Periodontal Changes in a Population of Sjögren's and Sicca Syndrome Treated by Pilocarpine: A Pilot Study. Rheumatology and Therapy, 2021, 8, 219-231.	1.1	4
8	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. Rheumatology, 2021, 60, 1364-1375.	0.9	26
9	Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade. Rheumatology and Therapy, 2021, 8, 751-760.	1.1	6
10	Ultrasonography of the Salivary Gland in Primary Sjögren Syndrome: Usefulness to Phenotype the Patients. Journal of Rheumatology, 2021, 48, 633-634.	1.0	2
11	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. Nature Communications, 2021, 12, 3523.	5.8	67
12	Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine, 2021, 88, 105221.	0.8	0
13	Healthy Patients Are Not the Best Controls for Microbiome-Based Clinical Studies: Example of Sjögren's Syndrome in a Systematic Review. Frontiers in Immunology, 2021, 12, 699011.	2.2	10
14	Impact of the COVID-19 pandemic on therapeutic management of rheumatoid arthritis in Brittany (France). Joint Bone Spine, 2021, 88, 105179.	0.8	2
15	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 329-338.	0.5	61
16	Application of the OMERACT synovitis ultrasound scoring system in juvenile idiopathic arthritis: a multicenter reliability exercise. Rheumatology, 2021, 60, 3579-3587.	0.9	11
17	Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary SjA¶gren's syndrome. Rheumatology, 2020, 59, 811-819.	0.9	23
18	A simplified radiographic score effectively predicts radiographic progression of early arthritis in a large nationwide French cohort. Rheumatology, 2020, 59, 1566-1573.	0.9	1

#	Article	IF	CITATIONS
19	Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sjögren's syndrome. Rheumatology, 2020, 59, 2350-2359.	0.9	54
20	The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmunity Reviews, 2020, 19, 102670.	2.5	26
21	ls Tocilizumab as efficient as steroids early in polymyalgia rheumatica?. Seminars in Arthritis and Rheumatism, 2020, 50, 582.	1.6	2
22	Seasonal effect on fatigue, pain and dryness in primary Sjögren's syndrome. Arthritis Research and Therapy, 2020, 22, 39.	1.6	8
23	Biopsies des glandes salivaires en rhumatologie. Revue Du Rhumatisme Monographies, 2020, 87, 184-188.	0.0	0
24	Should we use ultrasonography in the clinic to detect pSS?. Nature Reviews Rheumatology, 2019, 15, 642-643.	3.5	1
25	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	2.2	76
26	Salivary gland ultrasonography in primary Sjögren's syndrome: opportunities and challenges. Rheumatology, 2019, , .	0.9	28
27	Localized Myofascial Inflammation Revealed by Magnetic Resonance Imaging in Recent-onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy. Journal of Rheumatology, 2019, 46, 1619-1626.	1.0	17
28	Assessment of major salivary gland size in primary Sjögren's syndrome: Comparison between clinical examination and ultrasonography. Joint Bone Spine, 2019, 86, 627-632.	0.8	9
29	Pseudo-polyarthrite rhizomélique et artérite à cellules géantes en 2019. Revue Du Rhumatisme Monographies, 2019, 86, 199-206.	0.0	3
30	ls early-onset primary Sjögren's syndrome a worse prognosis form of the disease?. Rheumatology, 2019, 58, 1163-1167.	0.9	39
31	Efficacy of Epratuzumab, an Antiâ€ <scp>CD</scp> 22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	2.9	49
32	Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology, 2018, 57, 666-670.	0.9	25
33	Primary Sjögren's Syndrome Prevalence: What if Sjögren was Right After All? Comment on the Article by Maciel et al. Arthritis Care and Research, 2018, 70, 951-953.	1.5	8
34	Time-course of ultrasound abnormalities of major salivary glands in suspected Sjögren's syndrome. Joint Bone Spine, 2018, 85, 227-232.	0.8	29
35	What is the agreement between pathological features of parotid gland and labial salivary gland biopsies?. Annals of the Rheumatic Diseases, 2018, 77, e37-e37.	0.5	8
36	Évolution des anomalies observées à l'échographie des glandes salivaires principales dans les cas de suspicion de syndrome de Gougerot-Sjögren. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 465-470.	0.0	0

#	Article	IF	CITATIONS
37	Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Research and Therapy, 2018, 20, 11.	1.6	32
38	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1161-1168.	0.5	200
39	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjA¶gren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.5	132
40	Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica. Rheumatology, 2017, 56, 1401-1406.	0.9	24
41	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. RMD Open, 2017, 3, e000364.	1.8	87
42	Severe Healthâ€Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patientâ€Reported Outcomes: Data From a Large Therapeutic Trial. Arthritis Care and Research, 2017, 69, 528-535.	1.5	65
43	Comparison of 2002 AECC and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren's syndrome. Arthritis Research and Therapy, 2017, 19, 269.	1.6	77
44	High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary SjA¶gren's Syndrome: Data from the TEARS Randomized Trial. PLoS ONE, 2016, 11, e0162787.	1.1	43
45	Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?. RMD Open, 2016, 2, e000305.	1.8	9
46	Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. RMD Open, 2016, 2, e000205.	1.8	15
47	Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Annals of the Rheumatic Diseases, 2016, 75, 1506-1510.	0.5	124
48	Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open, 2016, 2, e000179.	1.8	88
49	Has the time come for biotherapies in giant cell arteritis and polymyalgia rheumatica?. Joint Bone Spine, 2016, 83, 471-472.	0.8	18
50	Treatment of primary Sjögren syndrome. Nature Reviews Rheumatology, 2016, 12, 456-471.	3.5	137
51	B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. Arthritis Research and Therapy, 2016, 18, 21.	1.6	20
52	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the Rheumatic Diseases, 2016, 75, 382-389.	0.5	225
53	Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. Rheumatology, 2016, 55, 789-800.	0.9	120
54	Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary SjĶgren's syndrome. Journal of Autoimmunity, 2016, 67, 102-110.	3.0	68

Valérie Devauchelle-Pense

#	Article	IF	CITATIONS
55	Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren's syndrome. Joint Bone Spine, 2016, 83, 681-685.	0.8	58
56	Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome?. Annals of the Rheumatic Diseases, 2016, 75, e33-e33.	0.5	19
57	Can ARFI elastometry of the salivary glands contribute to the diagnosis of Sjögren's syndrome?. Joint Bone Spine, 2016, 83, 301-306.	0.8	33
58	A prospective evaluation of dental and periodontal status in patients with suspected Sjögren's syndrome. Joint Bone Spine, 2016, 83, 235-236.	0.8	33
59	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. PLoS ONE, 2015, 10, e0133907.	1.1	19
60	Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2015, 67, 1623-1628.	2.9	85
61	Reliability of histopathological salivary gland biopsy assessment in Sjogren's syndrome: a multicentre cohort study. Rheumatology, 2015, 54, 1056-1064.	0.9	47
62	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology, 2015, 54, 1699-1708.	0.9	49
63	Lymphopenia in early arthritis: Impact on diagnosis and 3-year outcomes (ESPOIR cohort). Joint Bone Spine, 2015, 82, 417-422.	0.8	5
64	ANCA-associated vasculitis in patients with primary SjĶgren's syndrome: Detailed analysis of 7 new cases and systematic literature review. Autoimmunity Reviews, 2015, 14, 742-750.	2.5	52
65	Salivary gland ultrasound to diagnose Sjogren's syndrome: a claim to standardize the procedure. Rheumatology, 2015, 54, 199-200.	0.9	26
66	Is there specific neurological disorders of primary Sjögren's syndrome?. Joint Bone Spine, 2015, 82, 86-89.	0.8	21
67	The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 49, 278-287.	2.9	49
68	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 249.	3.8	241
69	Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sjogren's syndrome. Rheumatology, 2014, 53, 1604-1607.	0.9	101
70	Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren's syndrome. Arthritis Research and Therapy, 2014, 16, R15.	1.6	33
71	Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepancies. Arthritis Research and Therapy, 2014, 16, R74.	1.6	42
72	Treatment of Primary Sjögren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 161, 377.	2.0	3

#	Article	IF	CITATIONS
73	Treatment of Primary Sjögren Syndrome With Rituximab. Annals of Internal Medicine, 2014, 160, 233-242.	2.0	325
74	Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: A systematic review. Autoimmunity Reviews, 2013, 12, 416-420.	2.5	146
75	Contribution of salivary gland ultrasonography to the diagnosis of Sjögren's syndrome: Toward new diagnostic criteria?. Arthritis and Rheumatism, 2013, 65, 216-225.	6.7	188
76	The future of B cell-targeted therapies in Sjögren's syndrome. Immunotherapy, 2013, 5, 639-646.	1.0	18
77	The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Annals of the Rheumatic Diseases, 2013, 72, 665-671.	0.5	110
78	Role of Fmsâ€like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary Sjögren's Syndrome. Arthritis and Rheumatism, 2013, 65, 3218-3227.	6.7	46
79	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary SJögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. PLoS ONE, 2013, 8, e59868.	1.1	147
80	Neurological Disorders in Primary Sjögren's Syndrome. Autoimmune Diseases, 2012, 2012, 1-11.	2.7	72
81	B cells in Sjögren's syndrome: From pathophysiology to diagnosis and treatment. Journal of Autoimmunity, 2012, 39, 161-167.	3.0	145
82	In Sjögren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmunity Reviews, 2012, 11, 252-258.	2.5	63
83	Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2011, 29, 6-12.	0.4	33
84	Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab. Arthritis and Rheumatism, 2010, 62, 2262-2271.	6.7	49
85	Significance of B cells and B cell clonality in Sjögren's syndrome. Arthritis and Rheumatism, 2010, 62, 2605-2610.	6.7	63
86	The Fmsâ€like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. Arthritis and Rheumatism, 2010, 62, 3447-3456.	6.7	55
87	Ability of oblique foot radiographs to detect erosions in early arthritis: Results in the ESPOIR cohort. Arthritis and Rheumatism, 2008, 59, 1729-1734.	6.7	27
88	Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis and Rheumatism, 2007, 57, 310-317.	6.7	280
89	Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis. Biologics: Targets and Therapy, 2007, 1, 311-9.	3.0	42
90	Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. Journal of Rheumatology, 2006, 33, 1511-5.	1.0	20

#	Article	IF	CITATIONS
91	ls periodontal disease mediated by salivary baff in sjögren's syndrome?. Arthritis and Rheumatism, 2005, 52, 2411-2414.	6.7	75
92	Diagnostic value of radiographs of the hands and feet in early rheumatoid arthritis. Joint Bone Spine, 2002, 69, 434-441.	0.8	17